Bin Cao

2 months ago | nature.com | Bin Cao

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03419-3, published online 7 January 2025. In the version of the article initially published, in Fig. 1, the boxes “194 were assigned to the suraxavir group” and “1 did not receive suraxavir” should have read “194 were assigned to the placebo group” and “1 did not receive the placebo” and have now been corrected in the HTML and PDF versions of the article. About this articleWang, Y., Wang, H., Zhang, Y. et al.

Jan 7, 2025 | nature.com | Bin Cao

AbstractSuraxavir marboxil (GP681) is an antiviral drug inhibiting the polymerase acidic protein (PA) of RNA polymerase, of influenza. It has shown therapeutic activity against influenza A and B virus infections in preclinical studies.

Dec 17, 2024 | mdpi.com | Bin Cao

1. Introduction 1.1. BackgroundThe rising focus on energy efficiency and enhancements in comfort represents a key challenge faced by the modern building industry. According to the International Energy Agency, the global energy consumption in buildings represents approximately 30% of the total energy consumption [1]. Buildings are crucial for providing occupants with suitable living and working environments, which are vital for their health and productivity [2].

Jul 11, 2024 | mdpi.com | Jianli Zhao |Yixin Chen |Bin Cao |Wenping Dou

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Apr 1, 2024 | dovepress.com | Bin Cao |Kun Li |Jing Ke |Dong Zhao

Bin Cao,1,2,* Kun Li,1,2,* Jing Ke,1,2 Dong Zhao1,2 1Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, People’s Republic of China; 2Beijing Key Laboratory of Diabetes Research and Care, Beijing, 101149, People’s Republic of China *These authors contributed equally to this work Correspondence: Jing Ke; Dong Zhao, Email [email protected]; [email protected] Objective: This study aimed to investigate the potential...